Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of Biogen Inc.. A complete text table follows the diagram.
Multiple sclerosis remains the largest product engine, but Alzheimer's collaboration revenue and newer rare-disease therapies are reshaping the neuroscience portfolio.
Swipe to explore
Every flow is a reported revenue category. Anti-CD20 and Alzheimer's collaboration revenue are separate from product sales because Biogen participates through collaboration economics.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Multiple Sclerosis products | 1 | $958M | TYSABRI, fumarates and interferons |
| Rare Disease products | 1 | $557M | SPINRAZA, SKYCLARYS and QALSODY |
| Biosimilars | 1 | $182M | European anti-inflammatory portfolio |
| Other products | 1 | $55.4M | Primarily ZURZUVAE |
| Biogen product revenue | 2 | $1.8B | Medicines sold directly |
| Anti-CD20 programs | 2 | $419M | Collaboration revenue stream |
| Alzheimer's collaboration | 2 | $59.5M | LEQEMBI economics |
| Manufacturing, royalties and other | 2 | $247M | External manufacturing and licenses |
| Biogen revenue | 3 | $2.5B | Neuroscience portfolio economics |
| From | To | Value |
|---|---|---|
| Multiple Sclerosis products | Biogen product revenue | $958M |
| Rare Disease products | Biogen product revenue | $557M |
| Biosimilars | Biogen product revenue | $182M |
| Other products | Biogen product revenue | $55.4M |
| Biogen product revenue | Biogen revenue | $1.8B |
| Anti-CD20 programs | Biogen revenue | $419M |
| Alzheimer's collaboration | Biogen revenue | $59.5M |
| Manufacturing, royalties and other | Biogen revenue | $247M |